|Celldex Posts Positive 3-Year Survival Data from Phase 2; Incyte Achieves Milestone on Phase III Development for RA|
|By Staff and Wire Reports|
|Thursday, 15 November 2012 20:42|
Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced the presentation of three-year survival data from the Phase 2 rindopepimut clinical program in EGFRvIII-positive glioblastoma—a more aggressive form of glioblastoma typically associated with reduced long-term survival in comparison to the glioblastoma population as a whole. Across three Phase 2 studies of rindopepimut, survival data remains consistent and suggests a substantial and continuing survival benefit in comparison to independent control datasets (see chart below) at the median and at three years.
In the multi-center Phase 2 ACT III study, the median overall survival is 24.6 months from diagnosis (21.8 months from study entry) and overall survival is 26% at three years. In the Phase 2 ACT II study, the median overall survival is 24.4 months from diagnosis (20.5 months from study entry) and overall survival is 23% at three years. In the Phase 2 ACTIVATE study, the median overall survival is 24.6 months from diagnosis (20.4 months from study entry) and overall survival is 33% at three years.
Incyte Corporation (NASDAQ: INCY) announced it has earned a $50 million milestone payment from Eli Lilly and Company based on the formal initiation of the rheumatoid arthritis (RA) Phase III program for baricitinib, Incyte's oral JAK1/JAK2 inhibitor, formerly known as INCB28050. The Phase III program is being conducted by Lilly as part of the exclusive worldwide License, Development and Commercialization Agreement for baricitinib.
Four Phase III RA studies are planned, which will investigate the safety and efficacy of baricitinib 2 mg and 4 mg once daily in patients with active RA who are methotrexate-naive, biologic-naive or biologic-experienced. Patients completing any of the four studies will be eligible for enrollment in a fifth study, a long-term extension. Information about the clinical trials can be viewed at www.clinicaltrials.gov.
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, today announced release 6.1 of the Accelrys Materials Studio® modeling and simulation environment, providing seamless integration with the Accelrys Pipeline Pilot scientific authoring application, the scientifically aware Accelrys Enterprise Platform and Accelrys Materials Studio Collection.
Aquentium, Inc. (OTCQB: AQNM) announced today that the company is planning on opening laser therapy clinics throughout the United States utilizing a new patented advanced low level laser therapy for individuals suffering from pain.
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the Piper Jaffray Annual Healthcare Conference in New York City.
AstraZeneca (NYSE:AZN) today announced that it is simplifying the enrollment process for the AZ&Me™ Prescription Savings Program for people with Medicare Part D by removing an out-of-pocket spend requirement.
AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and to improve lipid profiles in humans, today announced that it has received a Notice of Issuance for its patent application for Dissolution of Arterial Plaque
CardioNet, Inc. (NASDAQ:BEAT), the leading wireless medical technology company with a current focus on the diagnosis and monitoring of cardiac arrhythmias, today announced the launch of its new wireless event monitor, wEvent.
Cord Blood America, Inc. (OTC Bulletin Board: CBAI) ("CBAI" or the "Company") today announced financial results for the three and nine months periods ended September 30, 2012.
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Mark B. Knudson, Ph.D., EnteroMedics' President and Chief Executive Officer, is scheduled to participate in a "fireside chat" at the Piper Jaffray 24th Annual Healthcare Conference on November 28, 2012 at 2:00 pm Eastern Time at the New York Palace Hotel in New York.
FONAR Corporation (NASDAQ: FONR), The Inventor of MR Scanning™, reported today its first quarter financial results of fiscal 2013.
Given Imaging (NASDAQ: GIVN) today announced that Yuval Yanai, CFO, will present at the JP Morgan SMid Cap Conference taking place in New York City November 28 - 29, 2012.
Incyte Corporation (NASDAQ: INCY) announced today that it has earned a $50 million milestone payment from Eli Lilly and Company based on the formal initiation of the rheumatoid arthritis (RA) Phase III program for baricitinib, Incyte’s oral JAK1/JAK2 inhibitor, formerly known as INCB28050.
MMRGlobal, Inc. (OTCQB: MMRF) ("MMR") today announced that as reported in yesterday's quarterly filing on Form 10-Q for the period ended September 30, 2012, a minimum performance purchase Agreement was signed with VisiInc PLC ("Visi") for the sale of MMRPro systems.
mPhase Technologies, Inc. (OTCBB: XDSL) announced today that Pan European Networks has circulated a newsletter featuring contributions from mPhase Technologies and Professor Kostya Novoselov, a Nobel Prize winning researcher. Professor Novoselov was jointly awarded, with Andre Geim, The Nobel Prize in Physics 2010 for "groundbreaking experiments regarding the two-dimensional material graphene."
Positron Corporation (OTCBB:POSC), a nuclear medicine healthcare company, announced today the appointment of Charles Conroy as Chief Operating Officer.
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced financial results for the three and nine month periods ended September 30, 2012 and provided a business update.
Shire plc (LSE: SHP, NASDAQ: SHPG), announces that Jeff Jonas M.D. has been appointed President of Shire's Regenerative Medicine (RM) business, effective November 15, 2012.
University General Health System, Inc. (OTCQB: UGHS), a diversified, integrated multi-specialty health delivery system, today announced significantly improved operating results for the third quarter and first nine months of 2012.